Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007

Vaccine

Volumn 29, Issue 11, 2011, Pages 2029-2036

  Anh, D D ^a   Carlos, C C ^b   Thiem, D V ^a   Hutagalung, Y ^c   Gatchalian, S ^c   Bock, H L ^c   Smolenov, I ^c   Suryakiran, P V ^c   Han, H H ^c  

^a NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

^b RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

RIX4414 liquid formulation; Rotavirus vaccination schedule; The Philippines; Vietnam

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; PLACEBO; ROTAVIRUS VACCINE;

ARTICLE; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFANT; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHILIPPINES; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SEROCONVERSION; SIDE EFFECT; SUSPENSION; VIET NAM; VOMITING; WORLD HEALTH ORGANIZATION;

ANTIBODIES, VIRAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN A; INFANT; MALE; PHILIPPINES; POLIOVIRUS VACCINES; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED; VIETNAM;

EID: 79951814195     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.018     Document Type: Article

References (26)

1. Parashar U.D., Gibson C.J., Bresee J.S., Glass R.I. Rotavirus and severe diarrhea. Emerg Infect Dis 2006, 12:304-306.
2. WHO position paper. Wkly Epidemiol Rec 2007, 82(32):285-296.
3. Nguyen V.M., Le T.L., Dang D.T., Nguyen T.T., Phan V.T., Nguyen T.H., et al. Epidemiological profile and burden of rotavirus diarrhea in Vietnam: 5 years of sentinel hospital surveillance. J Infect Dis 2005, 192:S127-S132. 1998-2003.
4. Fischer T.K., Anh D.D., Antil L., Cat N.D.L., Kilgore P.E., Thiem V.D., et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005, 192:1720-1726.
5. Carlos C.C., Inobaya M.T., Bresee J.S., Lagrada M.L., Olorosa A.M., Kirkwood C.D., et al. The burden of hospitalizations and clinic visits for rotavirus disease in children aged <5 years in the Philippines. J Infect Dis 2009, 200:S174-S181.
6. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003, 9:565-572.
7. Forster J., Guarino A., Parez N., Moraga F., Román E., Mory O., et al. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. Pediatrics 2009, 123:393-400.
8. Inglis E., Kesson A., Newall A.T., Macartney K., MacIntyre C.R. The burden of rotavirus gastroenteritis in children presenting to a paediatric hospital. Epidemiol Infect 2009, 137:943-949.
9. van Damme P., Giaquinto C., Huet F., Gothefors L., Maxwell M., Van der M., et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe The REVEAL Study, 2004-2005. J Infect Dis 2007, 195:S4-S16.
10. Phua K.B., Lim F.S., Lau Y.L., Nelson E.A.S., Huang L.M., Quak S.H., et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomized, double-blind, controlled study. Vaccine 2009, 27:5936-5941.
11. Steele A.D, De Vos B., Tumbo J., Reynders J., Scholtz F., Bos P., et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2008, 28(39):6542-6548.
12. Dennehy P.H., Bertrand H.R., Silas P.E., Damaso S., Friedland L.R., Abu-Elyazeed R. Co-administration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States. Pediatrics 2008, 122(5):e1062-e1066.
13. Linhares A.C., Velázquez F.R., Pérez-Schael I., Sáez-Llorens X., Abate H., Espinoza F., et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomized, double-blind, placebo-controlled phase III study. Lancet 2008, 371:1181-1189.
14. Vesikari T, Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomized, double-blind controlled study. Lancet 2007, 370:1757-1763.
15. Wiedenmayer K.A., Weiss S., Chattopadhyay C., Mukherjee A., Kundu R., Ayé R., et al. Simplifying paediatric immunization with a fully liquid DTP-HepB-Hib combination vaccine: Evidence from a comparative time-motion study in India. Vaccine 2009, 27:655-659.
16. Vesikari T., Karvonen A., Suryakiran P.V., Smolenov I., Han H.H. Immunogenicity and reactogenicity of liquid versus lyophilized formulation of Rotarix™ (Rix4414) live-attenuated human rotavirus vaccine in Finland. 26th meeting of European society for paediatric infectious diseases 2008.
17. Bernstein D.I., Smith V.E., Sherwood J.R., Schiff G.M., Sander D.S., DeFeudis D., et al. Safety and immunogenicity of a live attenuated human rotavirus 89-12 vaccine. Vaccine 1998, 16:381-387.
18. Bernstein D.I., Sack D.A., Rothstein E., Reisinger K., Smith V.E., O'Sullivan D., et al. Efficacy of live attenuated human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet 1999, 354:287-290.
19. van Doorn L.J., Kleter B., Hoefnagel E., Stainier I., Poliszczak A., Colau B., et al. Detection and genotyping of human rotavirus VP4 and VP7 genes by reverse transcriptase PCR and reverse hybridization. J Clin Microbiol 2009, 47(9):2704-2712.
20. Patel M., Pedreira C., De Oliveira L.H., Tate J., Orozco M., Mercado J., et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009, 301(21):2243-2251.
21. Glass R.I., Parashar U.D., Bresee J.S., Turcios R., Fischer T.K., Widdowson M.A., et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006, 368:323-332.
22. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362:289-298.
23. Meeting of the immunization strategic advisory group of experts, April 2009-conclusions and recommendations. Wkly Epidemiol Rec 2009, 84(23):220-235.
24. Meeting of the strategic advisory group of experts on immunization, October 2009-conclusions and recommendations. Wkly Epidemiol Rec 2009, 84(50):517-532.
25. Ortega E., Rivera M., Rivera L., Nuñez E., Pavia Ruz N., Espinoza F., et al. High immunogenicity of two doses of the human monovalent G1P[8] rotavirus vaccine, Rotarix™ parallels high efficacy in a multicountry phase III study. Presented at the world congress of pediatric infectious diseases 2005.
26. Ruiz-Palacios G.M., Pérez-Schael I., Velázquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(1):11-22.